Mar 30, 2020
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology
Mar 18, 2020
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners
Mar 05, 2020
Allergan Receives FDA Approval for DURYSTA(TM) (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients
Jan 16, 2020
Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living
Oct 10, 2019
On World Sight Day, Allergan Launches National Campaign to Raise Awareness of the Toll Glaucoma Takes on Everyday Living
Oct 10, 2019
Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent
Sep 05, 2019
iSTAR Medical Announces EUR 40m Series C Financing
Aug 29, 2019
MIGS Devices Continue to Expand Use of Glaucoma Surgery
Apr 23, 2019
Ivantis Announces Publication of Landmark Comparative MIGS Clinical Trial Results in Leading Ophthalmic Journal
Mar 27, 2019
First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI(TM) Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures
Mar 14, 2019
Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
Mar 14, 2019
Clinical Study Demonstrates Long Term IOP Reduction with the OMNI® Surgical System Predicate Device (TRAB®360) in Micro-Invasive Glaucoma Surgery
Dec 19, 2018
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market to Reach a Market Size of $1,180.7 Million by 2024 - KBV Research
Aug 13, 2018
Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS)
Jun 13, 2018
Allergan Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (Sustained-Release) Implant for IOP Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension
Apr 16, 2018
Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial
Apr 12, 2018
New Data from the HORIZON Trial of the Hydrus® Microstent Shows Significantly Lower IOP and Medication Use at 24 Months in a US Patient Cohort
Feb 20, 2018
Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Expected to Reach $912 Million by 2023 - Allied Market Research
Nov 13, 2017
Ivantis FDA Clinical Trial of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials
Nov 10, 2017
Dr. Nathan Radcliffe to Present Latest Data on Kahook Dual Blade (KDB) at AAO 2017